Kras oncogene and pancreatic cancer: Thirty years after;Oncogène Kras et cancer du pancréas: Trente ans plus tard

Medecine/Sciences

Volumn 29, Issue 11, 2013, Pages 991-997

  Bournet, Barbara ^a   Dufresne, Marlène ^a   Selves, Janick ^a   Torrisani, Jérôme ^a   Cordelier, Pierre ^a   Buscail, Louis ^a  

^a CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADENOCARCINOMA; ANIMAL; FINE NEEDLE ASPIRATION BIOPSY; GENETICS; HUMAN; MOUSE; MUTATION; PANCREAS TUMOR; PATHOLOGY; REVIEW; TRANSGENIC MOUSE;

ADENOCARCINOMA; ANIMALS; BIOPSY, FINE-NEEDLE; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84889646927     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20132911015     Document Type: Review

References (33)

1. Hidalgo, M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617.
2. http://cancer.sanger.ac.uk/cancergenome/projects/cosmic
3. Torrisani, J; Buscail, L. Molecular pathways of pancreatic carcinogenesis. Ann Pathol 2002; 22: 349-355. (Pubitemid 35408089)
4. Berthélemy, P; Bouisson, M; Escourrou, J; et al. Identification of KRAS mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 1995; 123: 188-191.
5. Laghi, L; Orbetegli, O; Bianchi, P; et al. Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene 2002; 21: 4301-4306. (Pubitemid 34753836)
6. Hruban, RH; Wilentz, RE; Kern, SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000; 156: 1821-1825. (Pubitemid 30641750)
7. Hahn, WC; Counter, CM; Lundberg, AS; et al. Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464-468. (Pubitemid 29361801)
8. Hingorani, SR; Petricoin, EF; Maitra, A; et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-450. (Pubitemid 38050041)
9. Siveke, JT; Einwachter, H; Sipos, B; et al. Concomitant pancreatic activation of Kras(G12D) and Tgfî results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 2007; 12: 266-279. (Pubitemid 47333415)
10. Aguirre, AJ; Bardeesy, N; Sinha, M; et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17: 3112-3126. (Pubitemid 38040774)
11. Bardeesy, N; Aguirre, AJ; Chu, GC; et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006; 103: 5947-5952.
12. Hingorani, SR; Wang, L; Multani, AS; et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7: 469-483. (Pubitemid 40719130)
13. Kojima, K; Vickers, SM; Adsay, NV; et al. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia. Cancer Res 2007; 67: 8121-8130. (Pubitemid 47395147)
14. Izeradjene, K; Combs, C; Best, M; et al. Kras(G12D) and Smad4/DPC4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 2007; 11: 229-243. (Pubitemid 46349845)
15. Skoulidis, F; Cassidy, LD; Pisupati, V; et al. Germline BRCA2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 2010; 18: 499-509.
16. Guerra, C; Schuhmacher, AJ; Canamero, M; et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007; 11: 291-302. (Pubitemid 46349841)
17. Faca, VM; Song, KS; Wang, H; et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008; 5: e123.
18. Fendrich, V; Schneider, R; Maitra, A; et al. Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer. Neoplasia 2011; 13: 180-186.
19. Olive, KP; Jacobetz, MA; Davidson, CJ; et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461.
20. Bournet, B; Souque, A; Senesse, P; et al. EUS-guided fine needle-aspiration biopsy coupled to KRAS mutation assay to differentiate pancreatic cancer from pseudo-tumorous chronic pancreatitis. Endoscopy 2009; 41: 552-557.
21. Van Laethem, JL; Vertongen, P; Deviere, J; et al. Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours. Gut 1995; 36: 781-787.
22. Costentin, L; Pagès, P; Bouisson, M; et al. Frequent deletions of tumor suppressor genes in pure pancreatic juice from patients with tumoral or nontumoral pancreatic diseases. Pancreatology 2002; 2: 17-25. (Pubitemid 34639097)
23. Tada, M; Komatsu, Y; Kawabe, T; et al. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol 2002; 97: 2263-2270.
24. Pellisé, M; Castells, A; Ginès, A; et al. Clinical usefulness of KRAS mutational analysis in the diagnosis of pancreatic adenocarcinoma by means of endosonography-guided fine-needle aspiration biopsy. Aliment Pharmacol Ther 2003; 17: 1299-1307. (Pubitemid 36693731)
25. Takahashi, K; Yamao, K; Okubo, K; et al. Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA. Gastrointest Endosc 2005; 61: 76-79. (Pubitemid 40169815)
26. Maluf-Filho, F; Kumar, A; Gerhardt, R; et al. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass. J Clin Gastroenterol 2007; 41: 906-910. (Pubitemid 350307077)
27. Bournet, B; Muscari, F; Guimbaud, R; et al. KRAS mutations and their correlation with survival of patients with advanced pancreatic cancer. Pancreas 2013; 42: 543-544.
28. Shin, SH; Kim, SC; Hong, S-M; et al. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas 2013; 42: 216-222.
29. Lièvre, A; Bachet, JB; Le Corre, D; et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
30. Laurent-Puig, P. Critères biologiques d-éligibilité pour un traitement anti-EGFR. Med Sci (Paris) 2009; 25: 21-24.
31. Galmiche, A; Ezzoukhry, Z. Régulation de la survie cellulaire par les kinases de la famille RAF. Med Sci (Paris) 2010; 26: 729-733.
32. Viret, F; Gonçalves, A. Cancers colorectaux métastatiques et thérapies ciblées anti-EGF. Med Sci (Paris) 2009; 25: 13-21.
33. Ahearn, IM; Haigis, K; Bar-Sagi, D; Philips, MR. Regulating the regulator: post-translational modification of Ras. Nat Rev Mol Cell Biol 2012; 13: 39-51.